Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company's products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue. Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles. The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. Proteonomix, Inc. was incorporated in 1995 and is based in Hawthorne, New Jersey.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PROT
Previous Symbol
CUSIPN/A
Phone+1-973-5446116
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable
Stromacel (OTCMKTS:PROT) Frequently Asked Questions
What is Stromacel's stock symbol?
Stromacel trades on the OTCMKTS under the ticker symbol "PROT."
Has Stromacel been receiving favorable news coverage?
Press coverage about PROT stock has been trending somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Stromacel earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of Stromacel's key competitors?
Some companies that are related to Stromacel include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE).
Who are Stromacel's key executives?
Stromacel's management team includes the folowing people:
- Mr. Michael Cohen, Founder, Chairman, CEO, Pres & COO (Age 51)
- Mr. Steven Byle, CTO & Director (Age 50)
- Mr. Jason B. Isaacs, Sec. (Age 46)
- Ms. Jaci Mandil, Chief Exec. Officer of Proteoderm
How do I buy shares of Stromacel?
Shares of PROT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stromacel's stock price today?
One share of PROT stock can currently be purchased for approximately $0.01.
What is Stromacel's official website?
How can I contact Stromacel?
Stromacel's mailing address is 187 Mill Ln, MOUNTAINSIDE, NJ 07092-2918, United States. The biotechnology company can be reached via phone at +1-973-5446116.
MarketBeat Community Rating for Stromacel (OTCMKTS PROT)
MarketBeat's community ratings are surveys of what our community members think about Stromacel and other stocks. Vote "Outperform" if you believe PROT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PROT will underperform the S&P 500 over the long term. You may vote once every thirty days.
